Condition Lookup

Central Sleep Apnea (CSA)

Category: Sleep-Related Respiratory Disorders

Symptoms:
interrupted breathing during sleep; frequent awakenings; excessive daytime sleepiness; morning headaches; difficulty concentrating; irritability; dry mouth upon waking

Root Cause:
Reduced or absent respiratory drive from the brainstem, leading to insufficient breathing effort during sleep.

How it's Diagnosed: videos
Polysomnography (sleep study) to detect absence of airflow without respiratory effort and evaluation of patient history and symptoms.

Treatment:
Addressing underlying conditions (e.g., heart failure, opioid use), supplemental oxygen, adaptive servo-ventilation (ASV), and CPAP in select cases.

Medications:
For CSA due to opioid use, reducing or discontinuing opioids may help. Acetazolamide (carbonic anhydrase inhibitor) may be prescribed to stimulate breathing in certain cases.

Prevalence: How common the health condition is within a specific population.
Less common than OSA; prevalence varies but can occur in up to 5% of patients undergoing polysomnography for sleep complaints.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Heart failure, stroke, opioid use, high-altitude exposure, and certain neurological conditions.

Prognosis: The expected outcome or course of the condition over time.
Depends on the underlying cause; treating the root condition often improves CSA. Persistent CSA may lead to worsened cardiovascular outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Heart arrhythmias, worsened heart failure, hypoxemia, and impaired quality of life.

Obesity Hypoventilation Syndrome

Specialty: Pulmonology

Category: Sleep-Related Respiratory Disorders

Sub-category: Hypoventilation Syndromes

Symptoms:
daytime sleepiness; fatigue; shortness of breath; headaches (especially in the morning); difficulty concentrating; loud snoring; interrupted sleep

Root Cause:
Impaired breathing due to excess weight causing mechanical and metabolic effects that disrupt normal respiratory function, leading to elevated carbon dioxide (CO2) and reduced oxygen (O2) levels.

How it's Diagnosed: videos
Diagnosis involves clinical evaluation, arterial blood gas analysis to detect hypercapnia, overnight polysomnography to assess sleep-disordered breathing, and ruling out other causes of hypoventilation (e.g., lung disease).

Treatment:
Treatment focuses on weight loss through lifestyle changes, bariatric surgery if indicated, and non-invasive positive pressure ventilation (e.g., CPAP or BiPAP) during sleep to improve breathing.

Medications:
Medications such as acetazolamide (a carbonic anhydrase inhibitor) may be used to stimulate breathing and reduce CO2 levels in select cases.

Prevalence: How common the health condition is within a specific population.
OHS affects approximately 0.15–0.3% of the general population and 10–20% of individuals with severe obesity.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Severe obesity (BMI greater than or equal to 30 kg/m²), sleep apnea, male gender, advancing age, and underlying respiratory disorders.

Prognosis: The expected outcome or course of the condition over time.
With appropriate treatment, symptoms and quality of life can improve significantly. However, untreated OHS can lead to severe complications and increased mortality.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Pulmonary hypertension, right-sided heart failure (cor pulmonale), systemic hypertension, and increased risk of cardiovascular morbidity and mortality.

Congenital Central Hypoventilation Syndrome

Specialty: Pulmonology

Category: Sleep-Related Respiratory Disorders

Sub-category: Hypoventilation Syndromes

Symptoms:
difficulty breathing during sleep; cyanosis (bluish skin); reduced oxygen levels; chronic fatigue; learning difficulties in older children; difficulty regulating heart rate and blood pressure

Root Cause:
A genetic mutation (commonly in the PHOX2B gene) leads to impaired autonomic control of breathing, particularly during sleep, resulting in hypoventilation and reduced CO2 elimination.

How it's Diagnosed: videos
Diagnosis is based on clinical symptoms, genetic testing for PHOX2B mutations, polysomnography, and blood gas analysis.

Treatment:
Lifelong mechanical ventilation support (e.g., diaphragmatic pacemakers, CPAP, or BiPAP), tracheostomy in severe cases, and management of associated autonomic dysfunction.

Medications:
Medications are not typically prescribed for this condition directly. However, respiratory stimulants like caffeine or theophylline may be used in neonates to support breathing.

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated prevalence of 1 in 200,000 live births.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of CCHS and known genetic mutations (PHOX2B).

Prognosis: The expected outcome or course of the condition over time.
With proper management, individuals can live into adulthood, but lifelong dependence on ventilatory support and monitoring for associated conditions is required.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Pulmonary hypertension, cor pulmonale, arrhythmias, neurocognitive impairments, and difficulties with physical activities due to reduced respiratory reserve.